Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2013-10-16

Original market date: See footnote 1

1991-12-31

Product name:

TRAVASOL

Description:

BLEND C

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

00872296

Product Monograph/Veterinary Labelling:

Date: 2020-04-01 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

BAXTER CORPORATION
7125 Mississauga Road
Mississauga
Ontario
Canada L5N 0C2

Class:

Human

Dosage form(s):

Solution

Route(s) of administration:

Intravenous

Number of active ingredient(s):

15

Schedule(s):

Ethical

 

American Hospital Formulary Service (AHFS): See footnote 3

40:20.00 

Anatomical Therapeutic Chemical (ATC): See footnote 4

B05BA01 AMINO ACIDS

Active ingredient group (AIG) number:See footnote5

1517080002

List of active ingredient(s)
Active ingredient(s) Strength
ARGININE 1.15 G / 100 ML
GLYCINE 1.03 G / 100 ML
HISTIDINE 480 MG / 100 ML
ISOLEUCINE 600 MG / 100 ML
L-ALANINE 2.07 G / 100 ML
L-LYSINE (L-LYSINE HYDROCHLORIDE) 580 MG / 100 ML
LEUCINE 730 MG / 100 ML
METHIONINE 400 MG / 100 ML
PHENYLALANINE 560 MG / 100 ML
PROLINE 680 MG / 100 ML
SERINE 500 MG / 100 ML
THREONINE 420 MG / 100 ML
TRYPTOPHAN 180 MG / 100 ML
TYROSINE 40 MG / 100 ML
VALINE 580 MG / 100 ML
Version 4.0.2
Date modified: